Q-omics provides the consensus-scored ZBTB11 profile across patient tissues and cancer cell-line models. ZBTB11 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZBTB11 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, ZBTB11 RNA expression shows 20,466 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, HNSC, and ACC as cancer lineages where ZBTB11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB11 survival associations across molecular data types. ZBTB11 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB11 RNA expression–survival associations across cancer types. High ZBTB11 expression shows unfavorable associations in ACC, LIHC, UCEC and KICH, but favorable associations in UCS and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for ZBTB11 RNA expression.
This table summarizes ZBTB11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB11 shows higher tumor expression in HNSC, LIHC, COAD, BLCA, BRCA and CHOL. The HNSC box plot shows higher ZBTB11 RNA expression in tumor versus normal tissue (log2 FC = +0.927, t-test p < 0.001).
This table shows molecular features associated with ZBTB11 in patient tissues and cancer cell lines. In patient samples, ZBTB11 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
